PM
LGND icon

Parametrica Management’s Ligand Pharmaceuticals LGND Stock Holding History

Parametrica Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-2,717
Closed -$206K – 393
2017
Q2 		$206K Sell
2,717
-394
-13% -$27.6K 0.19% 225
2017
Q1 		$205K Buy
+3,111
New +$205K 0.21% 253

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DMK
David M. Knott $275M AUM 59.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Parametrica Management's LGND Position: Q3 2017 in Review

Parametrica Management sold out of Ligand Pharmaceuticals (LGND) in Q3 2017, closing a stake of 2,717 shares — an estimated $206K sold.

Parametrica Management first reported a position in LGND in Q1 2017 and held it in 2 quarters. The position peaked at $206K in Q2 2017. 293 funds tracked by Wall St. Rank hold LGND as of Q3 2017.

  • Parametrica Management reported no remaining Ligand Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Parametrica Management sold 2,717 Ligand Pharmaceuticals shares in Q3 2017, an estimated $206K.
  • Parametrica Management first reported a position in Ligand Pharmaceuticals in Q1 2017 and held it in 2 quarters.
  • Parametrica Management's Ligand Pharmaceuticals position peaked at $206K in Q2 2017.
  • 293 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2017.

Based on Parametrica Management's 13F filing for Q3 2017, filed 27 Oct 2017.